In a groundbreaking case report recently published in npj Parkinson’s Disease, researchers have unveiled a unique intersection between two enigmatic neurological conditions: Parkinson’s disease (PD) and isolated congenital anosmia with absent olfactory bulbs. This unexpected clinical finding challenges conventional understanding of the role of olfactory structures in PD pathology and opens new avenues for exploring early disease mechanisms. The detailed analysis elucidates a patient who presents classical motor symptoms of Parkinson’s disease despite a lifelong absence of olfactory bulbs and complete anosmia, suggesting intriguing implications for neurodegenerative disease research.
Parkinson’s disease is a progressive neurodegenerative disorder primarily characterized by motor dysfunction, including bradykinesia, rigidity, resting tremor, and postural instability. Traditionally, one of the earliest non-motor symptoms associated with PD is hyposmia or loss of smell, which typically precedes motor manifestations by several years. This olfactory dysfunction has been linked to the involvement of the olfactory bulb and related brain regions in the earliest stages of Lewy body pathology. The case report, however, throws this well-established progression into question by documenting PD in an individual who was born without olfactory bulbs and had never experienced the sense of smell.
Congenital anosmia refers to the lifelong absence of the sense of smell, often due to developmental anomalies where the olfactory bulbs or nerves fail to form properly. The olfactory bulbs, situated in the anterior cranial fossa, are the first relay station for olfactory information and have critical connections to limbic and cortical areas. Their absence typically results in irreversible anosmia but is generally regarded as a benign condition without broader neurological consequences. The novelty of this report lies in the co-occurrence of congenital anosmia with confirmed Parkinsonian pathology, raising the question of whether olfactory dysfunction is a cause, an effect, or an epiphenomenon of the neurodegenerative cascade.
The patient described in the study demonstrated classical cardinal signs of Parkinson’s disease around middle age, including progressive motor impairment and a positive response to dopaminergic therapy. Notably, detailed MRI scans confirmed the complete absence of olfactory bulbs, a rare congenital anomaly that had persisted since birth. This morphological absence was corroborated by lifelong anosmia confirmed via standardized olfactory testing paradigms. Importantly, the patient’s family history was unremarkable for neurodegenerative disorders, suggesting a sporadic rather than hereditary form of the disease.
This case compels a reconsideration of the olfactory hypothesis of Parkinson’s disease pathogenesis, which posits that misfolded alpha-synuclein aggregates may originate in the olfactory mucosa and spread centrally through the olfactory bulb. If PD pathology manifested without any olfactory bulb input, alternative anatomical pathways or mechanisms must be implicated in disease initiation. This supports a multifocal or systemic origin model of Parkinson’s disease rather than a purely olfactory tract-based one, underscoring the complex heterogeneity of disease onset.
From a neuropathological standpoint, the report highlights the importance of examining extranigral structures in PD, particularly the role of the olfactory system as a gateway for environmental toxins, pathogens, or abnormal protein propagation. The absence of olfactory bulbs eliminates this gateway, yet does not confer protection against neurodegeneration. This finding raises critical questions about alternative entry routes for pathological alpha-synuclein, such as the gut-brain axis or brainstem nuclei, reaffirming the emerging paradigm of Parkinson’s disease as a multisystem disorder with diverse etiologies.
In clinical terms, the report serves as a cautionary note against overreliance on olfactory testing as a diagnostic marker for prodromal Parkinson’s disease in certain populations. While olfactory dysfunction remains a robust biomarker in the majority of PD cases, congenital anosmics may never manifest this hallmark despite developing motor Parkinsonism. This necessitates developing more comprehensive screening strategies that consider the full spectrum of sensory capabilities when assessing early PD risk.
Furthermore, the patient’s longitudinal clinical trajectory provides significant insights into disease progression free from olfactory network involvement. Disease severity, dopaminergic responsiveness, and cognitive decline metrics aligned with typical Parkinsonian profiles, suggesting that olfactory bulb abnormalities do not modify the classical clinical phenotype extensively. This bolsters the genetic and molecular underpinnings of PD as primary determinants of disease course, with sensory deficits potentially acting as modifiers rather than prerequisites.
This case also has profound implications for research on neurodevelopment and neurodegeneration. The coexistence of a developmental anosmia phenotype alongside adult-onset neurodegeneration underscores the lifelong plasticity and vulnerability of the nervous system. It highlights a need to investigate how congenital structural brain anomalies may intersect with and influence late-onset neurodegenerative processes, potentially through shared molecular pathways or compensatory neuroplastic mechanisms.
Technological advancements in neuroimaging and molecular diagnostics were pivotal in this investigation. High-resolution MRI protocols enabled precise visualization of absent olfactory bulbs, while detailed olfactory psychophysical tests confirmed anosmia with high sensitivity. Coupled with advanced dopaminergic challenge tests and clinical rating scales, these methods provided a comprehensive phenotype delineation. The integration of multimodal data sets exemplifies the future of precision medicine approaches in unraveling complex neurological syndromes.
Moreover, this report fuels the debate on whether anosmia represents a mere symptom or an active pathogenic player in Parkinson’s disease. If olfactory dysfunction is not indispensable for PD onset, it may instead reflect downstream network degeneration rather than inciting pathology. Consequently, therapeutic efforts targeting olfactory circuits may require re-evaluation regarding their capacity to alter disease course or improve patient outcomes.
The report also draws attention to the broader implications for sensory neuroscience, particularly how the loss of one sensory modality interacts with neurodegenerative processes. The adaptive and maladaptive remodeling of neural circuits in response to absent olfactory input, and their subsequent susceptibility to proteinopathies, is an exciting frontier. This may expand understanding of cross-modal compensations and vulnerabilities in degenerative diseases.
Importantly, the rarity of this case highlights the value of case report literature in neurology. Such singular yet meticulously documented instances can challenge dogma, provoke critical re-examination of existing models, and inspire new directions for hypothesis-driven research. As big data and population studies continue to dominate, this work reinforces the enduring worth of detailed individual patient analysis.
Looking forward, validation of these findings in larger cohorts with congenital anosmia is essential. Longitudinal surveillance of such individuals may identify additional cases of neurodegeneration, clarify risk factors, and refine models of PD etiology. Integrating genetic screening, environmental exposure assessment, and detailed sensory phenotyping will accelerate discovery of potential protective or predisposing factors linked to olfaction.
In summary, this case report fundamentally shakes up the understanding of Parkinson’s disease pathophysiology by establishing that the hallmark olfactory bulb is not a prerequisite for the disease onset. The findings provoke new hypotheses about alternative pathological pathways, refine biomarker paradigms, and inspire further research into the intersection of neurodevelopmental abnormalities and adult neurodegeneration. As research advances, such unique clinical insights will be pivotal in shaping future diagnostic and therapeutic strategies in Parkinson’s disease and neurodegeneration at large.
Subject of Research: Parkinson’s disease and isolated congenital anosmia with absent olfactory bulbs
Article Title: Case report of Parkinson’s disease in isolated congenital anosmia with absent olfactory bulbs
Article References:
Brosse, S., Postuma, R.B., Shechter, Y. et al. Case report of Parkinson’s disease in isolated congenital anosmia with absent olfactory bulbs. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01386-9
Image Credits: AI Generated
Tags: absence of olfactory bulbs in Parkinson’sanosmia and Parkinson’s disease case studycongenital anosmia clinical implicationsearly non-motor symptoms of Parkinson’sisolated congenital anosmia and neurodegenerationLewy body pathology and smell lossmotor symptoms without olfactory impairmentneurobiology of Parkinson’s diseaseneurodegenerative disease mechanismsolfactory dysfunction in Parkinson’s diseaseParkinson’s disease progression without olfactory inputParkinson’s disease with congenital anosmia
